Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cumberland Pharmaceuticals (CPIX) Minority Interest: 2009-2024

Historic Minority Interest for Cumberland Pharmaceuticals (CPIX) over the last 16 years, with Dec 2024 value amounting to -$307,517.

  • Cumberland Pharmaceuticals' Minority Interest fell 3.05% to -$319,150 in Q3 2025 from the same period last year, while for Sep 2025 it was -$319,150, marking a year-over-year decrease of 3.05%. This contributed to the annual value of -$307,517 for FY2024, which is 10.49% up from last year.
  • Latest data reveals that Cumberland Pharmaceuticals reported Minority Interest of -$307,517 as of FY2024, which was up 10.49% from -$343,572 recorded in FY2023.
  • Cumberland Pharmaceuticals' 5-year Minority Interest high stood at -$117,116 for FY2020, and its period low was -$343,572 during FY2023.
  • Over the past 3 years, Cumberland Pharmaceuticals' median Minority Interest value was -$307,517 (recorded in 2024), while the average stood at -$314,405.
  • As far as peak fluctuations go, Cumberland Pharmaceuticals' Minority Interest crashed by 211.31% in 2020, and later climbed by 10.49% in 2024.
  • Yearly analysis of 5 years shows Cumberland Pharmaceuticals' Minority Interest stood at -$117,116 in 2020, then crashed by 81.30% to -$212,328 in 2021, then plummeted by 37.58% to -$292,126 in 2022, then declined by 17.61% to -$343,572 in 2023, then increased by 10.49% to -$307,517 in 2024.